Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy
- Conditions
- Prostate CancerObesity
- Interventions
- Behavioral: Weight Loss ProgramBehavioral: Standardized educational flyerBehavioral: Weight Maintenance Program
- Registration Number
- NCT03261271
- Lead Sponsor
- University of Kansas Medical Center
- Brief Summary
The purpose of this study is to test how a weight management program affects substances in the blood called biomarkers that can show the presence or severity of cancer, compared to a standardized diet and exercise educational flyer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 40
- Men newly diagnosed with PCa who are scheduled for radical prostatectomy (RP) (T1 or T2)
- Body Mass Index (BMI) 25-45 kg/m2
- Has internet access
- History of 5 alpha reductase inhibitors prior 3 months
- History of radiation therapy for cancer treatment
- Taking active cancer treatment
- Undergoing salvage therapy
- Castration-resistant PCa
- Evidence of metastasis
- Evidence of biochemical recurrence
- High risk medical condition (e.g. kidney disease, uncontrolled diabetes, etc.)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Weight Loss and Weight Maintenance Weight Loss Program Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery. Weight Loss and Weight Maintenance Weight Maintenance Program Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery. Control Standardized educational flyer Participants will receive a standardized educational flyer about a healthy diet and exercise.
- Primary Outcome Measures
Name Time Method Impact of Weight Loss Before and Weight Maintenance After Prostate Cancer (PCa) Surgery on Immunosuppressive Factors Change from Baseline to Month 6 Impact will be measured by changes in specific blood immune biomarker monocytic myeloid-derived suppressor cells (mMDSCs). The absolute number of cell counts were calculated using the lymphocyte count abstracted from the complete blood count with differential.
- Secondary Outcome Measures
Name Time Method Change in Weight Change from Baseline to Month 6 Body weight will be measured at participant study visits.
Impact of Weight Loss Before and Weight Maintenance After PCa Surgery on Inflammation Factors Change from Baseline to Month 6 Impact will be measured by changes in specific blood biomarker leptin/adiponectin ratio.
Change in Body Composition Change from Baseline to Study End Body composition will be measured using a Dual Energy X-Ray Absorptiometry (iDXA). Change in percent body fat will be analyzed between groups from baseline to study end.
Change in Quality of Life Change from Baseline to Month 6 Quality of Life will be measured using the Expanded PCa Index Composite (EPIC) Instrument-26. There are a total of 26 items on the survey. Scores range from 0 to 100. The higher the score, the higher the quality of life.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States